Update marks the first MDMA-assisted therapy session at a Numinus clinic VANCOUVER, BC, March 30, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has advanced to the next implementation phase in the clinical…


Previous articleatai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
Next articleSilo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study